
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. is highlighted for its promising upside potential in valuation, which effectively balances the inherent risks associated with its operations and the opportunities that lie ahead. The company's diversified product pipeline, which includes innovations like EsoGuard, esocheck, and the Veris Cancer Care Platform, indicates strong growth prospects, particularly in the upcoming years of 2025 and 2026. Furthermore, PAVmed's current valuation is considered attractive, supporting a positive sentiment about its trajectory as the company advances its early-stage products toward more significant commercial success.
Bears say
PAVmed Inc reported a pro forma net loss of $0.8 million, translating to an earnings per share (EPS) of $(0.05), which is significantly better than the prior estimates that projected a loss ranging between $(0.13) and $(0.25). This financial performance is overshadowed by a decline in the usage of its flagship EsoGuard test, with processed tests dropping to 2,756 in Q2 from 3,034 in Q1 and an overall downward trend from previous quarters. Additionally, the company faces substantial risks, including liquidity challenges, regulatory hurdles, market competition, and shifts in healthcare priorities, all of which cast a shadow over its ability to sustain growth and profitability.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares